Julphar reports strong full year 2021 Financial Results


Gulf Pharmaceutical Industries PJSC (Julphar), one of the largest pharmaceutical manufacturers in the Middle East and Africa, has reported its year end 2021 Financial Results, with robust topline growth and a return to a profitable bottomline, demonstrating the effectiveness of its corporate strategy and laying the foundations for future expansion in its product offering and geographic footprint.

The Company reported strong topline growth with 2021 revenues of AED 1,143 million, a 100 percent increase as compared to full year 2020* revenue of AED 573 million, which is primarily attributable to increased market share in key operating regions including the United Arab Emirates and the Kingdom of Saudi Arabia and the contribution from Planet Pharmacies LLC acquisition in July 2021.

In 2021, Julphar reported EBITDA from Continuing Operations at AED 164.8 million, up from a negative EBTIDA of AED -165.8 million in 2020*. This growth is due to sales increase and cost savings, in addition to the acquisition and subsequent consolidation of Planet Pharmacies, allowing Julphar to realise synergies across production and distribution.

By the middle of 2021, the Company marked a return to profit, and closed out the year with robust net profits at AED 63.9 million, as compared to an operating loss of AED 241.6 million for full year 2020*. The Company’s profit after tax for full year 2021 reached AED 59.4 million, as compared to a loss of AED 317.4 million in 2020, which serves to underline the Company’s strategy for growth, and is bolstered by the divestment of non-core assets.

Sheikh Saqer Humaid Al Qasimi, Chairman of the Board, Julphar, said: “The return to profitability is testament to the unwavering commitment of the management team to enact effective strategies that create sustainable growth. Julphar is focused on the continued development of its core business to provide affordable and quality health care solutions in the MENA region.”

Dr. Essam Mohamed, Chief Executive Officer of Julphar, said: “The Company’s 2021 financial results demonstrate strong topline and bottomline growth. Underscored by sales increase and cost-saving, the strategic acquisition of Planet Pharmacies, and Julphar’s cash flow positive position primes it for further growth opportunities as it continues its drive to bring its first-in-class new products and new added value medicines throughout the region.”

Looking to 2022, the Company will continue to enact its corporate strategy while investing in its in-house research and development function. Julphar will also continue to build new partnerships to bring high-quality generics and first-in-class treatments to the region to serve patient needs better. Julphar is planning to launch more than 15 new products in 2022, with the aim of securing local supply chains of critical pharmaceuticals and life-saving medicines, supporting the manufacturing of high-quality products locally by implementing new cutting-edge technologies in line with the UAE government healthcare agenda.

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, refer to our Cookie Policy.